INHIBRX BIOSCIENCES, INC. Increase Decrease In Operating Lease Liability
INHIBRX BIOSCIENCES, INC. (INBX) reported Increase Decrease In Operating Lease Liability of -$1.11 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$563.00K.
- INHIBRX BIOSCIENCES, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$549.00K.
- INHIBRX BIOSCIENCES, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$535.00K.
- INHIBRX BIOSCIENCES, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$522.00K.
- INHIBRX BIOSCIENCES, INC. increase decrease in operating lease liability for fiscal 2025 was -$1.59M.
- INHIBRX BIOSCIENCES, INC. increase decrease in operating lease liability for fiscal 2024 was -$1.41M.
- INHIBRX BIOSCIENCES, INC. increase decrease in operating lease liability for fiscal 2023 was -$1.86M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$563.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.11M 10-Q · filed 2026-08-13 | -$1.65M derived: sum of 3 quarters · filed 2026-08-13 | -$2.17M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$549.00K 10-Q · filed 2026-05-14 | -$1.08M derived: sum of 2 quarters · filed 2026-05-14 | -$1.61M derived: sum of 3 quarters · filed 2026-05-14 | -$1.97M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$535.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$1.06M derived: sum of 2 quarters · filed 2026-03-19 | -$1.42M derived: sum of 3 quarters · filed 2026-08-13 | -$1.59M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$522.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$889.00K derived: sum of 2 quarters · filed 2026-08-13 | -$1.06M 10-Q · filed 2025-11-14 | -$1.13M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$367.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$538.00K 10-Q · filed 2026-08-13 | -$608.00K derived: sum of 3 quarters · filed 2026-08-13 | -$944.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$171.00K 10-Q · filed 2026-05-14 | -$241.00K derived: sum of 2 quarters · filed 2026-05-14 | -$577.00K derived: sum of 3 quarters · filed 2026-05-14 | -$1.08M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$70.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$406.00K derived: sum of 2 quarters · filed 2026-03-19 | -$913.00K derived: sum of 3 quarters · filed 2026-03-19 | -$1.41M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$336.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$843.00K derived: sum of 2 quarters · filed 2025-11-14 | -$1.34M 10-Q · filed 2025-11-14 | -$1.82M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$507.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$1.00M 10-Q · filed 2025-08-13 | -$1.49M derived: sum of 3 quarters · filed 2025-08-13 | -$1.96M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$495.00K 10-Q · filed 2025-05-14 | -$979.00K derived: sum of 2 quarters · filed 2025-05-14 | -$1.45M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | -$484.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$957.00K derived: sum of 2 quarters · filed 2025-03-17 | -$1.86M 10-K · filed 2025-03-17 | |
| 2023-09-30 | -$473.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$1.38M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | -$903.00K 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |